

Press Release  
28 October 2024 10:00:00 CET



## Newbury Pharmaceuticals Secures Generic Approval for Buspiron

**Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Buspiron tablets in Sweden.**

*“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). Based on this positive outcome of the regulatory process, we will proceed to launch this product” says Mr Lars Minor CEO of Newbury*

The annual value of the market is estimated to be 0,9 MEUR according to DLMI Nordic Pharma Insights.

**For more information, contact:**

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

### **About Newbury Pharmaceuticals**

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.

### **Attachments**

---

[Newbury Pharmaceuticals Secures Generic Approval for Buspiron](#)